Evolus’ 2025 Playbook: Profitability, Progress, and a 2028 EBITDA Dream

Key numbers at a glance (ticker: EOLS)

Evolus, Inc. (ticker: EOLS) delivered a 2025 that leans into profitability after multiple years of growth. For the fourth quarter, Total Net Revenue reached $90.3 million, with full-year revenue totaling $297.2 million. On the earnings texture, the company reports GAAP Operating Income of $4.2 million in Q4 and Non-GAAP Operating Income of $7.1 million for the same period. The year closed with GAAP Operating Expenses of $229.8 million and Non-GAAP Operating Expenses of $209.7 million, landing within its prior guidance.

Importantly, Evolus highlighted a shift in cost structure in the second half of 2025, with expenses declining about 4% in the latter half versus the first half. The company also laid out a forward-looking Revenue Forecast for 2026 of $327–$337 million, which implies a 10%–13% lift from 2025 results. On the margin front, management targets a 2026 Adjusted EBITDA margin in the low- to mid-single digits, and a longer-run objective of 13%–15% by 2028, as it pursues meaningful leverage across a higher revenue base.

What the executives said

“In 2025 we generated nearly $300 million in total net revenue delivering our sixth consecutive year of double-digit growth,” said David Moatazedi, Evolus President and CEO. He emphasized that the company’s “performance beauty” positioning, backed by clinically differentiated products, supports continued outperformance in the aesthetic market and a broader injectable portfolio, including Evolysse and the planned Sculpt initiative.

Moatazedi also framed the profitability step as deliberate: “We achieved profitability in the fourth quarter, reflecting the benefits of decisive expense actions... while preserving our growth trajectory.” The team signaled that 2026 hinges on revenue momentum accompanied by disciplined non-GAAP expense growth, and a commitment to capital flexibility as the portfolio scales.

Line-item highlights and what they imply

Revenue momentum: 2025 full-year revenue of $297.2 million with Q4 at $90.3 million suggests sustained demand for Evolus’ injectable portfolio.
Profitability ahead: Q4 GAAP profitability and non-GAAP operating income demonstrate the company’s path toward sustained margins as it leverages scale and cost discipline.
Guidance discipline: 2026 revenue forecast of $327–$337 million indicates a solid top-line lift, while 2026 non-GAAP OpEx is guided to only a 0%–3% year-over-year increase, reinforcing leverage potential.
Margin expansion horizon: The 2026 target of a low- to mid-single-digit Adjusted EBITDA margin, with a longer-term 13%–15% by 2028, signals a staged commitment to profitability through product launches and operating leverage.
Pipeline and geography: The European launch of Estyme and the U.S. Sculpt initiative point to a growth runway beyond core brands, potentially broadening the company’s earnings sustainability.

Strategic read: what this might portend for Evolus and peers

Evolus is moving from a growth-at-all-costs phase to a more balanced model that prioritizes profitability without sacrificing its revenue trajectory. The measured 2026 revenue forecast, paired with controlled non-GAAP expense growth, suggests management is aiming to translate scale into operating leverage—an outcome investors often reward with higher cash flow and a more robust EPS base later in the cycle.

The 2028 guidance on Adjusted EBITDA margin of 13%–15% hints at a multi-year margin-by-build strategy: push through commercialization cost with higher volume, optimize the cost structure, and selectively invest in growth engines like Estyme and Sculpt. If the company can sustain mix improvements—shifting toward higher-margin products and expanding international reach—the trajectory toward EPS growth could become more tangible, even when reported on a per-share basis that includes stock-based compensation and non-cash items.

For the sector, Evolus’ playbook echoes a broader theme: governance around operating expenses must align with revenue cadence, and investors will increasingly look for EPS consensus alignment with the company’s revenue forecast and the real-time durability of its pipeline. The emphasis on regulatory-compliant launches in Europe and accelerated U.S. product introductions may elevate expectations for peers that rely on a handful of blockbuster products. In short, profitability isn’t just a buzzword here; it’s a capital allocation discipline that could redefine how the aesthetics space prices growth versus risk.

Implications for sector peers

If Evolus can credibly execute its 2026–2028 margin roadmap while expanding revenue through international launches, peers might feel pressure to demonstrate similar leverage or to accelerate profitability timelines. The narrative shifts from “grow at any cost” to “grow at a sustainable rate with improving margins,” which could re-rate companies that are structurally sound but have lagged on cost discipline.

Investors will be watching how competitors balance product innovation with cost control, and whether the industry can sustain double-digit top-line growth while delivering meaningful EPS upside and managing earnings surprise risks. The next several quarters could define whether a handful of players become value compounds or remain high-variance growth bets.

What to watch next

Actual EPS and EPS consensus for Q4 and full-year results, once reported.
Any earnings surprise versus consensus, and how guidance for 2026 evolves with subsequent quarterly results.
Progress of Estyme in Europe and Sculpt in the U.S., and their impact on the revenue forecast and margin mix.
Free cash flow trajectory and capital allocation decisions that could affect the stock’s risk/reward profile.

Bottom line

Evolus has stitched a narrative of steady growth with an explicit profitability pivot. The 2026 revenue forecast sits beside a disciplined path to improving margins, and the longer-run 13%–15% Adjusted EBITDA target provides a clear if ambitious frame for investors. In a sector where product launches and pricing power matter, Evolus is betting that scale, geographic expansion, and disciplined cost management can convert growth into durable earnings—and perhaps move the needle on EPS consensus as the story unfolds.